4 research outputs found
Table_1_Giant cell arteritis: A population-based retrospective cohort study exploring incidence and clinical presentation in Canterbury, Aotearoa New Zealand.DOCX
Background/aimTo determine the epidemiology and clinical features of giant cell arteritis (GCA) in Canterbury, Aotearoa New Zealand, with a particular focus on extra-cranial large vessel disease.MethodsPatients with GCA were identified from radiology and pathology reports, outpatient letters and inpatient hospital admissions in the Canterbury New Zealand from 1 June 2011 to 31 May 2016. Data was collected retrospectively based on review of electronic medical records.ResultsThere were 142 cases of GCA identified. 65.5% of cases were female with a mean age of 74.2 years. The estimated population incidence for biopsy-proven GCA was 10.5 per 100,000 people over the age of 50 and incidence peaked between 80 and 84 years of age. 10/142 (7%) people were diagnosed with large vessel GCA, often presenting with non-specific symptoms and evidence of vascular insufficiency including limb claudication, vascular bruits, blood pressure and pulse discrepancy, or cerebrovascular accident. Those with limited cranial GCA were more likely to present with the cardinal clinical features of headache and jaw claudication. Patients across the two groups were treated similarly, but those with large vessel disease had greater long-term steroid burden. Rates of aortic complication were low across both groups, although available follow-up data was limited.ConclusionThis study is the first of its kind to describe the clinical characteristics of large vessel GCA in a New Zealand cohort. Despite small case numbers, two distinct subsets of disease were recognized, differentiating patients with cranial and large vessel disease. Our results suggest that utilization of an alternative diagnostic and therapeutic approach may be needed to manage patients with large vessel disease.</p
Additional file 1: of Factors associated with oral glucocorticoid use in patients with rheumatoid arthritis: a drug use study from a prospective national biologics registry
ARAD list of current ethics approvals across Australia. (DOCX 19 kb
Additional file 2: of Gout prevalence and predictors of urate-lowering therapy use: results from a population-based study
Table S1. Prevalence of gout by age group and gender from the South Australian 2015 Health Omnibus Survey. Table S2. Birth country prevalence (percentage). Odds ratios are for the comparison of participants with and without gout. Table S3. (A) Coefficients from the multinomial logistic regression model for predictors of allopurinol use. (B) Predictor variables not included in the model for allopurinol use. (PDF 236 kb
Additional file 1: of Gout prevalence and predictors of urate-lowering therapy use: results from a population-based study
The spring 2015 SAHOS study questions. (PDF 816 kb